You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of the UValidate platform for the profiling of topically applied chemical agents.
SBC: AMELIA TECHNOLOGIES LLC Topic: RProject Summary Skin is the first line of defense against the outside environment. When the skin barrier is breached by UV irradiation (UVR) or toxic chemicals, living cell layers including epidermal keratinocytes, melanocytes and dermal fibroblasts are subjected to DNA damage. If unrepaired, this damage can lead to photoaging and cutaneous carcinogenesis. In fact, skin cancer is by far the most c ...
STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of (R,S')-MNF as a dual-targeted therapy for pancreatic cancer
SBC: PAZ PHARMACEUTICALS LLC Topic: NCISummary Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer death in the U.S. with a 5-year survival rate of andlt;9%. The poor prognosis is partially due to resistance to standard of care treatments including gemcitabine (Gem) and Gem+nab-paclitaxel (n-PTX). The transcription factors HIF-1α and c-MYC are at the center of the mechanisms producing Gem and n-PTX resistance ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Novel Ophthalmic Product for Corneal Infections and Injuries
SBC: BIOLYTX PHARMACEUTICALS CORP Topic: NEIBiolytx Pharmaceuticals Corp. is developing a peptide, BP001, derived from the human endogenous host defense protein CAP37, as a novel multi-target ophthalmic product for corneal infections and injuries. The standard-of-care for corneal infections is topical administration of antibiotics that may be accompanied by topical steroids, to limit the destructive effect of the resulting corneal inflammat ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Development of a Digital Cognitive Screening Test to detect Mild Cognitive Impairment and Dementia in Clinical Settings.
SBC: EchoWear LLC Topic: NIAProject Summary Alzheimer’s disease and related dementias are a growing health problem in our aging population. Assessment of cognitive functioning for early detection is critical to identify individuals who might benefit from treatment with the available symptomatic medications for mild dementia as well as future disease-modifying therapies that are actively under development and being tested i ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
Promoting adult hippocampal neurogenesis in Alzheimer's Disease using an antibody-based therapy
SBC: BOLDEN THERAPEUTICS, INC. Topic: RPROJECT SUMMARY Alzheimer's disease (AD) is a looming public health crisis that threatens millions of patients' ability to experience healthy aging. In addition to the challenges that AD poses to patients, healthcare providers and caregivers, there is also tremendous economic burden associated with AD and related dementias – estimated to be well over $200B/year in the United States alone. Hundre ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
SnapCap: a device to decontaminate central venous catheters (CVC) with 5 snaps
SBC: Contech Medical, Inc. Topic: NICHDProject Summary/Abstract We propose a new approach to the decontamination of central venous catheters and the prevention of central line-associated bloodstream infections (CLABSI), an important healthcare-associated infection. CLABSIs cost the US healthcare system approximately $2.3 billion annually (Pronovost, NEJM, 2009). Additionally, CLABSIs can be life threatening, especially in the very youn ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Learning from the Ebola success: Can a mAb also save lives after yellow fever infection?
SBC: Mabloc, LLC Topic: NIAIDAbstract PROJECT SUMMARY/ABSTRACT The recent groundbreaking experiment using a single neutralizing monoclonal antibody (nmAb) to reduce the death rate in Ebola virus (EBOV)-infected individuals highlights the importance of this class of drug in the treatment of infectious disease. In August 2019, Dr. Anthony Fauci announced that administration of mAb114 had reduced the death rate from 70% to appro ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Developing Nanopieces, a Platform RNAi Delivery Technology for Treatment of Multiple Diseases
SBC: Nanode Therapeutics, Inc. Topic: NCATSSTTR_Developing Nanopieces 7. Project Summary/Abstract The bottleneck of developing new RNAi (RNA Interference) drugs is the lack of highly efficient and non-toxic RNA delivery to non-liver tissues in vivo. It is especially challenging to deliver negatively-charged nucleic acid into avascular, dense, and negatively-charged matrix in hard-to-reach tissues including joint cartilage. NanoDe Therapeut ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Disposable, medication-integrated tactile and motion sensor for glaucoma therapy compliance improvement
SBC: RETINAL CARE INC Topic: NABSTRACT Glaucoma is the leading cause of irreversible blindness in the world. The number of people with primary open angle glaucoma is expected to exceed 100 million by 2040. The first-line therapy for glaucoma treatment is patient-administered hypotensive medication delivered topically via an eye drop. However, studies have consistently shown that patients rarely adhere to dosing recommendations ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy
SBC: STRYKAGEN CORPORATION Topic: ODAbstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with a predicted incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The 7β1 integrin is a transmembrane linkage system in skeleta ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health